newsfilter
← Latest News
Business Wire·

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

- Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leadi